Skip to main content
Premium Trial:

Request an Annual Quote

Twist Alliance CNTG NGS Target Enrichment Panels

Twist Bioscience and Centogene have launched three next-generation sequencing target enrichment panels to support rare disease and hereditary cancer research as well as diagnostics. All three panels were curated using the Centogene Biodatabank, which contains data or samples from 700,000 patients. The Twist Alliance CNTG Exome Panel relies on a core exome, mitochondrial genome, and other content for enhanced coverage of genes and variants related to rare diseases. The Twist Alliance CNTG Rare Disease Panel includes more than 2,500 rare disease-associated genes, such as for treatable diseases, early-onset childhood disorders, cardiac disorders, neurodgenerative diseases, skeletal abnormalities, and metabolic disorders. The Twist Alliance CNTG Hereditary Oncology Panel includes 72 cancer-associated genes, such as those for hereditary breast cancer, gastrointestinal tumors, Li-Fraumeni syndrome, MEN1, MEN2, and paragangliomas.